For example, OLT117 has been shown to disrupt the IL-1β/IL-6/STAT3 axis in the TME, which decreases the immunosuppressive activity of MDSCs and improves anti-tumor immunity when combined with anti-PD-1 therapy [181]. Here, PDCD1 is linked to neoplasm.